Skin

Wojcinski, Zbigniew W.; Andrews-Jones, Lydia; Aibo, Daher Ibrahim; Kikkawa, Rie; Dunstan, Robert W.

doi:10.1201/9780429504624-21

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the female groups, uterine dilation, a common finding in rats at necropsy as it is related to the female hormonal cycle (NTP & DHHS, 2014), was found at similar frequency in both the control and treatment groups without inflammation or correlating findings in other tissues sensitive to endocrine disruption; therefore, the finding was considered non‐pathological and due to the normal estrous cycle. The hard subcutaneous formations found on the thighs of one female in each of the mid‐ and high‐dose groups were diagnosed as benign basal cell tumors upon histopathological examination, which can be a common finding in older rats in their skin or other organs (Mecklenburg et al, 2013; Wojcinski et al, 2013; Yamate, 2018).…”

Section: Discussionmentioning

confidence: 99%

A 90‐day toxicity study of tripeptide, arginine‐alanine‐lysine

Dunn

Glávits²,

Murbach

et al. 2023

J of Applied Toxicology

View full text Add to dashboard Cite

There is a growing global interest in using peptides in the health industry for pharmaceuticals, cosmetics, and natural food products. Peptides contain two or more linked amino acids, whereas more than 50 amino acids are classified as polypeptides.Although there is a growing level of interest in the use of peptides in the health and wellness industry, there is a lack of literature pertaining to a specific tripeptide derived from arginine, alanine, and lysine (RAK) that is of interest for human dietary use. Therefore, a 90-day repeated-dose toxicity study was performed in rats to evaluate the subchronic oral toxicity of RAK. Eighty Han:WIST rats were administered RAK by gavage at doses of 0, 250, 500, or 1000 mg/kg bw/day. There were no mortalities or other treatment related effects, and no target organs were identified. A no-observed-adverse-effect-level (NOAEL) of 1000 mg/kg bw/day, the highest dose tested, was determined. This study will contribute to the body of research in regard to the safety of the use of RAK.

show abstract

Section: Discussionmentioning

confidence: 99%